Delaying treatment with recommended statin therapy for patients with type 1 and 2 diabetes leads to significantly higher rates of cardiovascular events over a 10-year follow-up period. Those who accepted the recommended statin therapy from the start had a 6.4% risk of adverse CV events, compared to 8.5% for those who delayed. The risk for a cardiovascular event was 30% higher for patients who delayed statin therapy. Factors contributing to non-acceptance include concerns over side effects and a lack of symptoms before a serious event occurs. Clinicians should provide detailed information and involve family members in the decision-making process to help high-risk patients make well-informed decisions about their treatment options.
Source link
Delaying Statin Therapy in Diabetes Increases CV Risk
